Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $10MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Shukla Abhinav A. | Chief Technical Officer | Jul 06 '26 | Option Exercise | $3.57 | 12,153 | $43,386 | 98,533 | Jul 07 07:00 PM |
| Shukla Abhinav A. | Chief Technical Officer | Jul 02 '26 | Option Exercise | $3.57 | 410 | $1,464 | 86,790 | Jul 07 07:00 PM |
| Shukla Abhinav A. | Chief Technical Officer | Jul 02 '26 | Sale | $7.01 | 410 | $2,874 | 86,380 | Jul 07 07:00 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.